Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Paediatrics

Ivacaftor shows good safety profile in young children

Research shows that cystic fibrosis drug ivacaftor is well tolerated but needs close monitoring in patients aged 2–5 years.

Research shows that cystic fibrosis drug ivacaftor is well tolerated but needs close monitoring in patients aged 2-5 years. In the image, coloured x-ray of a lung with cystic fibrosis

Source: BSIP VEM / Science Photo Library

Younger children treated with the cystic fibrosis drug ivacaftor may require more frequent monitoring than older children, research suggests

Since 2012, the cystic fibrosis drug ivacaftor has been approved in Europe for patients aged six years and over with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, but its safety in younger patients is unknown.

In a study, reported in The Lancet Respiratory Medicine[1] (online, 20 January 2016), 33 children aged 2–5 years received ivacaftor for six months at doses of 50mg or 75mg every 12 hours.

The researchers say the safety profile was similar to that observed in adults, with cough (56%) and vomiting (29%) reported as the most common adverse events. However, they note that five children (15%) experienced elevations in liver function tests, suggesting younger patients would require more frequent monitoring.

The cohort is now being followed up to assess the long-term efficacy and safety of ivacaftor in this age group.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20200573

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Research shows that cystic fibrosis drug ivacaftor is well tolerated but needs close monitoring in patients aged 2-5 years. In the image, coloured x-ray of a lung with cystic fibrosis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.